H.C. Wainwright raised the firm’s price target on Harrow (HROW) to $70 from $69 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow announces U.S. FDA cleared an IND application for trial of Triesence
- Closing Bell Movers: MongoDB down over 20% after soft Q1 guidance
- Harrow Health Posts Record 2025 Results, Sets 2026 Outlook
- Harrow sees FY26 revenue $350M-$365M, consensus $386.39M
- Harrow reports Q4 EPS 17c vs. 24c last year